HK1145832A1 - Pyrimidine substituted purine derivatives - Google Patents

Pyrimidine substituted purine derivatives

Info

Publication number
HK1145832A1
HK1145832A1 HK10111517.9A HK10111517A HK1145832A1 HK 1145832 A1 HK1145832 A1 HK 1145832A1 HK 10111517 A HK10111517 A HK 10111517A HK 1145832 A1 HK1145832 A1 HK 1145832A1
Authority
HK
Hong Kong
Prior art keywords
compounds
purine derivatives
substituted purine
pyrimidine substituted
disorders
Prior art date
Application number
HK10111517.9A
Other languages
English (en)
Inventor
Harish Kumar Mysore Nagaraj
Williams Meredith
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of HK1145832A1 publication Critical patent/HK1145832A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK10111517.9A 2007-10-05 2010-12-10 Pyrimidine substituted purine derivatives HK1145832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US7553208P 2008-06-25 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (fr) 2007-10-05 2008-10-03 Dérivés de purine substitués par pyrimidine

Publications (1)

Publication Number Publication Date
HK1145832A1 true HK1145832A1 (en) 2011-05-06

Family

ID=40030252

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10111517.9A HK1145832A1 (en) 2007-10-05 2010-12-10 Pyrimidine substituted purine derivatives
HK15103837.4A HK1203488A1 (en) 2007-10-05 2015-04-21 Pyrimidine substituted purine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15103837.4A HK1203488A1 (en) 2007-10-05 2015-04-21 Pyrimidine substituted purine derivatives

Country Status (17)

Country Link
US (3) US8247410B2 (fr)
EP (1) EP2209786B1 (fr)
JP (2) JP5479346B2 (fr)
KR (3) KR20160116045A (fr)
CN (2) CN104119336B (fr)
AU (1) AU2008307798B2 (fr)
BR (1) BRPI0817503B8 (fr)
CA (1) CA2701581C (fr)
DK (1) DK2209786T3 (fr)
ES (1) ES2406129T3 (fr)
HK (2) HK1145832A1 (fr)
IL (2) IL204804A (fr)
MX (1) MX2010003668A (fr)
MY (1) MY150993A (fr)
RU (2) RU2518098C2 (fr)
WO (1) WO2009045175A1 (fr)
ZA (1) ZA201003118B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2209786B1 (fr) 2007-10-05 2013-02-27 Verastem, Inc. Dérivés de purine substitués par pyrimidine
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
JP2011527342A (ja) * 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Pi3kアイソフォーム選択的阻害剤
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2743015A1 (fr) * 2008-11-11 2010-05-20 Xcovery Holding Company Llc Inhibiteurs de la pi3k/mtor kinase
MX2011010105A (es) 2009-03-27 2012-01-12 Pathway Therapeutics Inc Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
US8754080B2 (en) 2009-04-03 2014-06-17 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (S) inhibitors
WO2010114494A1 (fr) * 2009-04-03 2010-10-07 S*Bio Pte Ltd Purines 2-morpholino 8-substituées pour une utilisation en tant qu'inhibiteurs de pi3k et/ou mtor dans le traitement de troubles prolifératifs
DK3072890T3 (en) 2009-07-07 2019-02-11 Mei Pharma Inc Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (fr) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Purines pontées à substitution morpholino
EP4438734A2 (fr) 2010-06-14 2024-10-02 The Scripps Research Institute Reprogrammation de cellules en un nouveau devenir
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
WO2012172043A1 (fr) 2011-06-15 2012-12-20 Laboratoire Biodim Dérivés de purine et leur utilisation comme produits pharmaceutiques pour prévenir ou traiter les infections bactériennes
IN2014CN04373A (fr) * 2011-12-05 2015-09-04 Novartis Ag
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
EP3059238B1 (fr) * 2013-10-16 2020-05-27 Shanghai Yingli Pharmaceutical Co. Ltd. Composé hétérocyclique condensé, son procédé de préparation, composition pharmaceutique et leurs utilisations
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
AR098721A1 (es) * 2013-12-11 2016-06-08 Biogen Idec Inc Inhibidores de biarilo de tirosina quinasa de bruton
WO2016109426A1 (fr) * 2014-12-29 2016-07-07 Verastem, Inc. Régime posologique oral d'un double inhibiteur de mtor et pi3
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
TR201910941T4 (tr) 2015-03-30 2019-08-21 Daiichi Sankyo Co Ltd 6-morfolinil-2-pirazolil-9H-pürin deriveleri ve PI3K inhibitörleri olarak kullanımları.
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
AR108665A1 (es) * 2016-06-02 2018-09-12 Celgene Corp Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania
ES2818620T3 (es) * 2016-06-16 2021-04-13 Janssen Pharmaceutica Nv Derivados de azabencimidazol como inhibidores de pi3k beta
CN110036109A (zh) 2016-12-02 2019-07-19 第一三共株式会社 新颖的内-β-N-乙酰基氨基葡糖苷酶
EP3621604A4 (fr) * 2017-03-31 2021-01-13 FTG Bio LLC Formes salines d'inhibiteur de kinase sélectif à base d'amino pyrazine purine
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
EP3630118A4 (fr) 2017-05-23 2021-03-31 MEI Pharma, Inc. Polythérapie
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
CN110950844B (zh) * 2018-09-27 2024-01-30 上海璎黎药业有限公司 吗啉基喹唑啉类化合物的晶型、其制备方法及应用
EP3897652A4 (fr) 2018-12-20 2022-09-14 KSQ Therapeutics, Inc. Pyrazolopyrimidines substituées et purines substituées et leur utilisation en tant qu'inhibiteurs de protéase 1 de traitement spécifique de l'ubiquitine
TW202233621A (zh) 2020-10-30 2022-09-01 美商Ksq治療公司 經取代吡唑并嘧啶之固態形式及其用途
WO2024041519A1 (fr) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
CA2320448C (fr) * 1998-02-26 2005-02-01 Aventis Pharmaceuticals Inc. 2-[trans-(4- aminocyclohexyl) amino]purines 6,9-disubstituees
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
JP4102664B2 (ja) * 2000-07-19 2008-06-18 ノバルティス アクチエンゲゼルシャフト バルサルタン塩
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
WO2003031406A2 (fr) 2001-10-12 2003-04-17 Irm Llc Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
AU2003265636A1 (en) 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
KR101052482B1 (ko) * 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2618513A1 (fr) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Derives heterocycliques insatures
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
EP2209786B1 (fr) 2007-10-05 2013-02-27 Verastem, Inc. Dérivés de purine substitués par pyrimidine
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
AU2009251291B2 (en) 2008-05-30 2013-05-02 F. Hoffmann-La Roche Ag Purine PI3K inhibitor compounds and methods of use
EP2310391A1 (fr) 2008-06-27 2011-04-20 S*BIO Pte Ltd Purines substituées par la pyrazine
JP2011527342A (ja) 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Pi3kアイソフォーム選択的阻害剤
US8754080B2 (en) 2009-04-03 2014-06-17 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (S) inhibitors
WO2010114494A1 (fr) 2009-04-03 2010-10-07 S*Bio Pte Ltd Purines 2-morpholino 8-substituées pour une utilisation en tant qu'inhibiteurs de pi3k et/ou mtor dans le traitement de troubles prolifératifs

Also Published As

Publication number Publication date
HK1203488A1 (en) 2015-10-30
US20130079512A1 (en) 2013-03-28
KR101701109B1 (ko) 2017-02-13
EP2209786B1 (fr) 2013-02-27
MY150993A (en) 2014-03-31
RU2518098C2 (ru) 2014-06-10
RU2014110894A (ru) 2015-07-10
BRPI0817503A2 (pt) 2015-05-05
US20100298319A1 (en) 2010-11-25
KR20100075609A (ko) 2010-07-02
IL235555A0 (en) 2014-12-31
CA2701581C (fr) 2016-12-20
JP5885729B2 (ja) 2016-03-15
KR20150063171A (ko) 2015-06-08
US8247410B2 (en) 2012-08-21
AU2008307798A1 (en) 2009-04-09
IL204804A0 (en) 2010-11-30
ES2406129T3 (es) 2013-06-05
CN101889015B (zh) 2014-06-04
CA2701581A1 (fr) 2009-04-09
RU2010117737A (ru) 2011-11-10
MX2010003668A (es) 2010-07-02
US8609838B2 (en) 2013-12-17
ZA201003118B (en) 2011-08-31
EP2209786A1 (fr) 2010-07-28
CN104119336A (zh) 2014-10-29
IL204804A (en) 2014-11-30
RU2681081C2 (ru) 2019-03-04
US20140066620A1 (en) 2014-03-06
CN101889015A (zh) 2010-11-17
KR20160116045A (ko) 2016-10-06
KR101643237B1 (ko) 2016-07-27
CN104119336B (zh) 2016-08-24
DK2209786T3 (da) 2013-06-03
AU2008307798B2 (en) 2013-10-03
JP2014139159A (ja) 2014-07-31
IL235555B (en) 2019-08-29
BRPI0817503B8 (pt) 2021-05-25
JP5479346B2 (ja) 2014-04-23
JP2010540625A (ja) 2010-12-24
WO2009045175A1 (fr) 2009-04-09
BRPI0817503B1 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
MY150993A (en) Pyrimidine substituted purine derivatives
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2012101654A3 (fr) Nouveaux composés de triazine
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MD4590B1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
WO2010111406A3 (fr) Composés et leurs utilisations thérapeutiques
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MX2012007175A (es) Derivados de imidazopiridina como inhibidores de jak.
IN2012DN02577A (fr)
WO2010025872A3 (fr) Inhibiteurs de npm-alk, ret, et bcr-abl à base d’alpha-carboline
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
MX2009006690A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2014016849A3 (fr) Nouveaux composés de triazine
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
WO2008140420A3 (fr) Dérivés de pyrimidine
WO2008140419A3 (fr) Dérivés de pyrimidine à substitution pyridyle
WO2008140421A3 (fr) Dérivés de pyrimidine à substitution hétérocycloalkyle
WO2009095712A3 (fr) Composés chimiques
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201003